JP2020518552A5 - - Google Patents

Download PDF

Info

Publication number
JP2020518552A5
JP2020518552A5 JP2019542485A JP2019542485A JP2020518552A5 JP 2020518552 A5 JP2020518552 A5 JP 2020518552A5 JP 2019542485 A JP2019542485 A JP 2019542485A JP 2019542485 A JP2019542485 A JP 2019542485A JP 2020518552 A5 JP2020518552 A5 JP 2020518552A5
Authority
JP
Japan
Prior art keywords
oligonucleotide
subunit
multimeric
multimer
stranded
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2019542485A
Other languages
English (en)
Japanese (ja)
Other versions
JP7183167B2 (ja
JP2020518552A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2018/017062 external-priority patent/WO2018145086A1/en
Publication of JP2020518552A publication Critical patent/JP2020518552A/ja
Publication of JP2020518552A5 publication Critical patent/JP2020518552A5/ja
Application granted granted Critical
Publication of JP7183167B2 publication Critical patent/JP7183167B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2019542485A 2017-02-06 2018-02-06 減少した腎クリアランスを有する多量体オリゴヌクレオチド Active JP7183167B2 (ja)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US201762455231P 2017-02-06 2017-02-06
US62/455,231 2017-02-06
US201762522363P 2017-06-20 2017-06-20
US62/522,363 2017-06-20
US201762561853P 2017-09-22 2017-09-22
US62/561,853 2017-09-22
PCT/US2018/017062 WO2018145086A1 (en) 2017-02-06 2018-02-06 Multimeric oligonucleotides having decreased kidney clearance

Publications (3)

Publication Number Publication Date
JP2020518552A JP2020518552A (ja) 2020-06-25
JP2020518552A5 true JP2020518552A5 (enExample) 2021-03-11
JP7183167B2 JP7183167B2 (ja) 2022-12-05

Family

ID=63039118

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2019542485A Active JP7183167B2 (ja) 2017-02-06 2018-02-06 減少した腎クリアランスを有する多量体オリゴヌクレオチド

Country Status (11)

Country Link
US (2) US11078484B2 (enExample)
EP (1) EP3576752A4 (enExample)
JP (1) JP7183167B2 (enExample)
KR (2) KR102623311B1 (enExample)
CN (1) CN110248665A (enExample)
AU (1) AU2018215684B2 (enExample)
CA (1) CA3051480A1 (enExample)
IL (2) IL307726A (enExample)
MX (1) MX2019009347A (enExample)
SG (1) SG11201906728TA (enExample)
WO (1) WO2018145086A1 (enExample)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101141544B1 (ko) 2009-03-13 2012-05-03 한국과학기술원 에스아이알엔에이 다중 접합체 및 이의 제조방법
IL316159A (en) * 2015-06-15 2024-12-01 Mpeg La Llc Defined Oligonucleotide Multimers and Methods for Manufacture Thereof
CN110248665A (zh) 2017-02-06 2019-09-17 Mpeg La有限责任公司 具有降低的肾清除的多聚体寡核苷酸
US20230287406A1 (en) * 2019-03-04 2023-09-14 Mpeg La, L.L.C. Multimeric oligonucleotides with enhanced bioactivity
AU2020252020A1 (en) * 2019-03-29 2021-11-11 University Of Massachusetts Oligonucleotide-based modulation of C90RF72
EP3966328A4 (en) 2019-05-06 2023-10-18 University Of Massachusetts Anti-c9orf72 oligonucleotides and related methods
US20230114023A1 (en) * 2019-07-30 2023-04-13 Mpeg La, L.L.C. Subcutaneous delivery of multimeric oligonucleotides with enhanced bioactivity
WO2021026476A1 (en) * 2019-08-08 2021-02-11 Mpeg La, L.L.C. Complement targeting with multimeric oligonucleotides
WO2021222635A2 (en) * 2020-04-30 2021-11-04 Mpeg La, L.L.C. Multimeric oligonucleotides with divided strands
EP4149557A4 (en) * 2020-05-13 2025-01-15 The University of North Carolina at Chapel Hill Nucleic acid ligand conjugates and use thereof for delivery to cells
WO2021236689A1 (en) * 2020-05-19 2021-11-25 Mpeg La, L.L.C. Orthogonally linked multimeric oligonucleotides
AU2024265748A1 (en) 2023-05-04 2025-10-23 Argonaute RNA Limited Dual silencing
GB2702002A (en) 2024-10-25 2026-05-27 Argonaute Rna Ltd Gene silencing of cardiovascular genes

Family Cites Families (52)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9207381D0 (en) * 1992-04-03 1992-05-13 Ici Plc Synthesis of oligonucleotides
US6218371B1 (en) 1998-04-03 2001-04-17 University Of Iowa Research Foundation Methods and products for stimulating the immune system using immunotherapeutic oligonucleotides and cytokines
WO2004030634A2 (en) 2002-10-02 2004-04-15 Alnylam Pharmaceuticals Inc. Therapeutic compositions
CA2518475C (en) 2003-03-07 2014-12-23 Alnylam Pharmaceuticals, Inc. Irna agents comprising asymmetrical modifications
JP2006522158A (ja) 2003-04-03 2006-09-28 アルナイラム ファーマシューティカルズ インコーポレイテッド ｉＲＮＡ複合体
US8969543B2 (en) 2003-04-03 2015-03-03 Bioneer Corporation SiRNA-hydrophilic polymer conjugates for intracellular delivery of siRNA and method thereof
WO2004091515A2 (en) 2003-04-09 2004-10-28 Alnylam Pharmaceuticals, Inc. iRNA CONJUGATES
AU2004230927B9 (en) 2003-04-13 2011-12-01 Enzon Pharmaceuticals, Inc. Polymeric oligonucleotide prodrugs
EP2669377A3 (en) 2003-04-17 2015-10-14 Alnylam Pharmaceuticals Inc. Modified iRNA agents
CA2522349A1 (en) 2003-04-17 2004-11-04 Alnylam Pharmaceuticals, Inc. Protected monomers
US7851615B2 (en) 2003-04-17 2010-12-14 Alnylam Pharmaceuticals, Inc. Lipophilic conjugated iRNA agents
EP1807520B1 (en) 2004-10-25 2012-07-25 Devgen NV Rna constructs
US20100003753A1 (en) 2005-08-01 2010-01-07 Purdue Research Foundation Multivalent rna nanoparticles for delivery of active agents to a cell
CA2648585C (en) 2006-04-07 2017-07-25 Idera Pharmaceuticals, Inc. Stabilized immune modulatory rna (simra) compounds for tlr7 and tlr8
US8748405B2 (en) 2007-01-26 2014-06-10 City Of Hope Methods and compositions for the treatment of cancer or other diseases
US20080214436A1 (en) 2007-01-26 2008-09-04 City Of Hope Methods and compositions for the treatment of cancer or other diseases
WO2008109373A1 (en) 2007-03-02 2008-09-12 Mdrna, Inc. Nucleic acid compounds for inhibiting erbb gene expression and uses thereof
WO2008109105A2 (en) 2007-03-06 2008-09-12 Flagship Ventures Methods and compositions for improved therapeutic effects with sirna
KR101343489B1 (ko) 2007-07-09 2013-12-20 이데라 파마슈티칼즈, 인코포레이티드 안정화된 면역 조절성 ｒｎａ（ｓｉｍｒａ）화합물
US8575123B2 (en) 2008-04-11 2013-11-05 Tekmira Pharmaceuticals Corporation Site-specific delivery of nucleic acids by combining targeting ligands with endosomolytic components
US9433684B2 (en) 2008-08-19 2016-09-06 Nektar Therapeutics Conjugates of small-interfering nucleic acids
US8637194B2 (en) 2008-09-02 2014-01-28 Bio-Nano Power, Llc Bio-nano power cells and their uses
BRPI0923225A2 (pt) 2008-12-02 2016-10-04 Chiralgen Ltd metodo para sintese de acidos nucleicos modificados no atomo de fosforo
WO2010090762A1 (en) 2009-02-04 2010-08-12 Rxi Pharmaceuticals Corporation Rna duplexes with single stranded phosphorothioate nucleotide regions for additional functionality
WO2010090452A2 (ko) * 2009-02-04 2010-08-12 성균관대학교산학협력단 세포 내 전달능이 증가된 작은 간섭 rna 복합체
KR101141544B1 (ko) 2009-03-13 2012-05-03 한국과학기술원 에스아이알엔에이 다중 접합체 및 이의 제조방법
HUE026020T2 (en) 2009-08-27 2016-05-30 Idera Pharmaceuticals Inc Preparation for inhibiting gene expression and its uses
KR101678876B1 (ko) 2010-01-15 2016-11-23 한국과학기술원 복합 유전자를 표적하는 ｓｉＲＮＡ 다중 접합체 및 이의 제조방법
PH12012501596A1 (en) 2010-02-24 2017-02-03 Arrowhead Res Corporation Compositions for targeted delivery of sirna
WO2011109380A1 (en) * 2010-03-01 2011-09-09 The Children's Hospital Of Philadelphia Nucleic acids for targeting multiple regions of the hcv genome
CN107365339A (zh) 2011-07-19 2017-11-21 波涛生命科学有限公司 合成官能化核酸的方法
KR101340290B1 (ko) * 2011-09-14 2013-12-11 한국과학기술원 유전자 표적용 ｓｉＲＮＡ 하이드로젤 및 그 제조방법
HK1200484A1 (zh) 2011-09-14 2015-08-07 Translate Bio Ma, Inc. 多聚寡核苷酸化合物
US20150247141A1 (en) 2012-09-14 2015-09-03 Rana Therapeutics, Inc. Multimeric oligonucleotide compounds
WO2014113802A1 (en) 2013-01-18 2014-07-24 H. Lee Moffitt Cancer Center And Research Institute, Inc. TARGETED SENSITIZATION OF NON-DEL(5q) MALIGNANT CELLS
KR101629681B1 (ko) 2013-06-24 2016-06-14 건국대학교 산학협력단 다중 리간드가 도입된 에스아이알엔에이 접합체
GB201311840D0 (en) * 2013-07-02 2013-08-14 Univ Aberdeen Control of varroa mite infestation
EP2845607A1 (en) 2013-09-09 2015-03-11 University of Vienna Antisense oligonucleotides with improved pharmacokinetic properties
WO2015089368A2 (en) 2013-12-12 2015-06-18 Alnylam Pharmaceuticals, Inc. Complement component irna compositions and methods of use thereof
US10358643B2 (en) 2014-01-30 2019-07-23 Hoffmann-La Roche, Inc. Poly oligomer compound with biocleavable conjugates
WO2016110691A1 (en) * 2015-01-06 2016-07-14 The University Court Of The University Of Aberdeen Enhanced rnai mediated gene regulation
IL316159A (en) 2015-06-15 2024-12-01 Mpeg La Llc Defined Oligonucleotide Multimers and Methods for Manufacture Thereof
WO2017004357A1 (en) 2015-07-02 2017-01-05 City Of Hope Compounds and compositions including phosphorothioated oligodeoxynucleotide, and methods of use thereof
WO2017075030A1 (en) 2015-10-26 2017-05-04 Rana Therapeutics, Inc. Methods and compositions for increasing smn expression
CA3010593C (en) 2016-01-05 2024-02-13 University Of Leicester Methods for inhibiting fibrosis in a subject in need thereof
JP7016317B2 (ja) 2016-08-08 2022-02-21 浩文 山本 アジュバント組成物
CN110248665A (zh) 2017-02-06 2019-09-17 Mpeg La有限责任公司 具有降低的肾清除的多聚体寡核苷酸
CN111164091B (zh) 2017-06-02 2025-01-07 波涛生命科学有限公司 寡核苷酸组合物及其使用方法
EP3733683A4 (en) 2017-11-30 2022-04-06 GeneMind Biosciences Company Limited NUCLEOSIDE ANALOGUES, METHOD OF MANUFACTURE AND USE
US20230287406A1 (en) 2019-03-04 2023-09-14 Mpeg La, L.L.C. Multimeric oligonucleotides with enhanced bioactivity
US20230114023A1 (en) 2019-07-30 2023-04-13 Mpeg La, L.L.C. Subcutaneous delivery of multimeric oligonucleotides with enhanced bioactivity
WO2021236689A1 (en) 2020-05-19 2021-11-25 Mpeg La, L.L.C. Orthogonally linked multimeric oligonucleotides

Similar Documents

Publication Publication Date Title
Zhou et al. Aptamers as targeted therapeutics: current potential and challenges
JP2018512155A5 (enExample)
TWI880645B (zh) 抑制lpa之基因表現之組合物及方法
R. Kanwar et al. Nucleic acid-based aptamers: applications, development and clinical trials
AU2014284836B2 (en) Respiratory disease-related gene specific siRNA, double-helical oligo RNA structure containing siRNA, compositon containing same for preventing or treating respiratory disease
TWI924663B (zh) 用於抑制ＰＮＰＬＡ３表現之ＲＮＡｉ劑、其醫藥組成物及使用方法
JP2015519047A5 (enExample)
JP2005517436A5 (enExample)
JP2014518612A5 (enExample)
JP2019503394A5 (enExample)
JP2021533804A5 (enExample)
JP2015518714A5 (enExample)
JP2014527401A5 (enExample)
CN110832077B (zh) 用于抑制α-ENaC表达的RNAi剂及使用方法
JP2025106480A5 (enExample)
JP2007529224A5 (enExample)
JP2016502858A5 (enExample)
JP2015523854A5 (enExample)
JP2020505032A5 (enExample)
JP2023514336A5 (enExample)
CN114585633A (zh) 寡核苷酸缀合物组合物和使用方法
JP6847852B2 (ja) 癌治療のためのヒト抗原Ｒ発現のｓｉＲＮＡ阻害
JP2022543191A5 (enExample)
EP3419988A1 (en) Novel prna three-way junctions
KR101390966B1 (ko) Ｈｉｆｌａ의 발현을 저해하는 ｓｉＲＮＡ 및 이를 포함하는 항암 조성물